56. Behcet disease Clinical trials / Disease details


Clinical trials : 76 Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116

  
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013901-33-DE
(EUCTR)
21/06/201003/03/2010A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303E1, SHIELD StudyA 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303E1, SHIELD Study Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
112France;Greece;Spain;Austria;Germany
2EUCTR2009-013901-33-GR
(EUCTR)
15/06/201022/02/2011A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
102Germany;France;Spain;Greece;Austria
3EUCTR2009-013901-33-FR
(EUCTR)
07/04/201016/02/2010A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapyA 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy Adjunctive therapy to standard-of-care for the treatment of intermediate uveitis, posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis
MedDRA version: 12.1;Classification code 10022557;Term: Intermediate uveitis
MedDRA version: 12.1;Classification code 10033687;Term: Panuveitis
Product Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
146France;Greece;Spain;Austria;Germany
4EUCTR2009-013901-33-ES
(EUCTR)
18/02/201018/01/2010Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveítis posterior o panuveítis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base - C2303E1Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveítis posterior o panuveítis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base - C2303E1 terapia adyuvante de los agentes inmunosupresores de base para el tratamiento de la uveítis posterior o de la panuveítis secundaria a la enfermedad de Behçet
MedDRA version: 9;Level: LLT;Classification code 10004212;Term: Behcet's disease
Product Name: AIN457
Product Code: AIN457
INN or Proposed INN: AIN457
Novartis Farmacéutica, S.A.NULLNot RecruitingFemale: yes
Male: yes
159Germany;France;Spain;Greece;Austria
5EUCTR2009-011237-27-DE
(EUCTR)
17/11/200906/08/2009A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's diseaseProduct Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
112Hungary;Germany;France;Spain;Italy;Greece;Austria
6EUCTR2009-013901-33-AT
(EUCTR)
12/11/200913/10/2009A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
112Germany;France;Spain;Greece;Austria
7EUCTR2009-011237-27-FR
(EUCTR)
23/10/200906/08/2009A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapyA 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10033687;Term: Panuveitis
MedDRA version: 12.0;Classification code 10036370;Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
INN or Proposed INN: Not available
Other descriptive name: rhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services AgNULLNot RecruitingFemale: yes
Male: yes
102France;Hungary;Greece;Spain;Austria;Germany;Italy
8EUCTR2009-011237-27-ES
(EUCTR)
20/10/200905/08/2009Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveitis posterior o panuveitis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base. - C2303Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveitis posterior o panuveitis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base. - C2303 Tratamiento de uveítis posterior o panuveítis secundaria a Behçet de forma aditiva al tratamiento inmunosupresor de base
MedDRA version: 9;Level: LLT;Classification code 10004212;Term: Behcet's disease
Product Name: AIN457
Product Code: AIN457
INN or Proposed INN: AIN457
Novartis Farmacéutica, S.A.NULLNot RecruitingFemale: yes
Male: yes
102Phase 3France;Hungary;Greece;Spain;Austria;Germany;Italy
9EUCTR2009-011237-27-HU
(EUCTR)
15/10/200929/07/2009A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Novartis Pharma Services AgNULLNot RecruitingFemale: yes
Male: yes
112France;Hungary;Greece;Spain;Austria;Germany;Italy
10EUCTR2009-011237-27-AT
(EUCTR)
14/10/200918/09/2009A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's diseaseProduct Name: AIN457
Product Code: AIN457
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
112Hungary;Germany;France;Spain;Italy;Greece;Austria
11NCT00995709
(ClinicalTrials.gov)
October 200913/10/2009Phase III Study in Refractory Behcet's DiseaseA 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive TherapyBehcet DiseaseDrug: AIN457;Drug: PlaceboNovartis PharmaceuticalsNULLCompleted18 YearsN/AAll118Phase 3United States;Egypt;France;Germany;Greece;Hong Kong;India;Israel;Italy;Jordan;Korea, Republic of;Singapore;Spain;Switzerland;Taiwan;Tunisia;Turkey;Austria;Brazil;Hungary;Saudi Arabia
12EUCTR2009-011237-27-GR
(EUCTR)
22/09/200907/10/2009A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's diseaseProduct Name: AIN457
Product Code: AIN457
Novartis Pharma Services AgNULLNot RecruitingFemale: yes
Male: yes
112Hungary;Germany;France;Spain;Italy;Greece;Austria